Dugal-Tessier Julien, Thirumalairajan Srinath, Jain Nareshkumar
NJ Bio, 675 US Highway 1, Suite B129, North Brunswick, NJ 08902, USA.
Seagen, 21717 30th Drive, S.E., Bothell, WA 98021, USA.
J Clin Med. 2021 Feb 18;10(4):838. doi: 10.3390/jcm10040838.
A summary of the key technological advancements in the preparation of antibody-oligonucleotide conjugates (AOCs) and the distinct advantages and disadvantages of AOCs as novel therapeutics are presented. The merits and demerits of the different approaches to conjugating oligonucleotides to antibodies, antibody fragments or other proteins, mainly from the perspective of AOC purification and analytical characterizations, are assessed. The lessons learned from in vitro and in vivo studies, especially the findings related to silencing, trafficking, and cytotoxicity of the conjugates, are also summarized.
本文介绍了抗体 - 寡核苷酸缀合物（AOCs）制备过程中的关键技术进展，以及AOCs作为新型治疗药物的明显优缺点。主要从AOC纯化和分析表征的角度，评估了将寡核苷酸与抗体、抗体片段或其他蛋白质缀合的不同方法的优缺点。还总结了体外和体内研究的经验教训，特别是与缀合物的沉默、转运和细胞毒性相关的发现。
